The aim of the present study was to analyze the prognostic role of combined PET and BCL2/IGH analysis, performed at the EOT, in a subset study of the phase III trial FOLL05 (NCT00774826), in which patients with FL were randomized to R-CVP (rituximab plus cyclophosphamide, vincristine and prednisone), R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or R-FM (rituximab plus fludarabine and mitoxantrone).6 This study was conducted in compliance with the Declaration of Helsinki, was approved by the appropriate research ethics committee, and required each patient to provide written informed consent.

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi / Luminari, Stefano; Galimberti, Sara; Versari, Annibale; Biasoli, Irene; Anastasia, Antonella; Rusconi, Chiara; Ferrari, Angela; Petrini, Mario; Manni, Martina; Federico, Massimo. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 101:2(2016), pp. e66-e68. [10.3324/haematol.2015.132811]

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi

LUMINARI, Stefano;MANNI, MARTINA;FEDERICO, Massimo
2016

Abstract

The aim of the present study was to analyze the prognostic role of combined PET and BCL2/IGH analysis, performed at the EOT, in a subset study of the phase III trial FOLL05 (NCT00774826), in which patients with FL were randomized to R-CVP (rituximab plus cyclophosphamide, vincristine and prednisone), R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or R-FM (rituximab plus fludarabine and mitoxantrone).6 This study was conducted in compliance with the Declaration of Helsinki, was approved by the appropriate research ethics committee, and required each patient to provide written informed consent.
2016
15-ott-2015
101
2
e66
e68
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi / Luminari, Stefano; Galimberti, Sara; Versari, Annibale; Biasoli, Irene; Anastasia, Antonella; Rusconi, Chiara; Ferrari, Angela; Petrini, Mario; Manni, Martina; Federico, Massimo. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 101:2(2016), pp. e66-e68. [10.3324/haematol.2015.132811]
Luminari, Stefano; Galimberti, Sara; Versari, Annibale; Biasoli, Irene; Anastasia, Antonella; Rusconi, Chiara; Ferrari, Angela; Petrini, Mario; Manni, Martina; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
422 (ex757).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1074788
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact